New hope for lung cancer patients: experimental drug ANS02 enters human trials
NCT ID NCT07538804
First seen May 03, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests a new drug, ANS02, in about 294 adults with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors. Participants must have tried other treatments or be unable to take standard therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
-
Research Site
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.